ArticleIBRO neuroscience reports2026
Association of circulating miR-210 with post-stroke seizures and clinical outcome: A preliminary study.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke seizure (PSS) is characterized by sudden, uncontrolled electrical activity in the brain following a stroke. Currently, reliable biomarkers for PSS are lacking. This study aimed to investigate serum levels of microRNA-210 (miR-210) as potential diagnostic and prognostic markers for PSS. Methods: Serum samples (2 mL) were collected from 40 patients with ischemic and hemorrhagic stroke (IS and HS) upon admission, along with 20 healthy controls. Serum miR-210 levels were measured using real-time PCR. Diagnostic and prognostic accuracy was assessed for miR-210 and the PoSERS model. Demographic and clinical data, including age, sex, stroke type, and stroke location, were recorded. The laboratory parameters, including white blood cells (WBCs), C-reactive protein (CRP), and erythrocyte sediment rate (ESR), were also assessed. Results: Significant differences were observed in stroke types (IS vs. HS) and stroke locations (cortical vs. subcortical) between patients with and without PSS (P < 0.05). Additionally, triglyceride (TG), HbA1C, and cholesterol levels differed significantly between these groups (P < 0.05). Serum miR-210 levels were significantly lower in stroke patients compared to healthy controls (P < 0.05). After one year of follow-up, miR-210 levels significantly differed between patients with and without PSS, as well as between survivors and non-survivors (P < 0.05). A negative correlation was found between circulating miR-210 and total cholesterol levels in stroke patients (r = -0.338, P < 0.05). However, miR-210 showed limited predictive value for PSS (AUC = 0.48), whereas the PoSERS model demonstrated good predictive performance (AUC = 0.77). Conclusions: Although circulating miR-210 was significantly associated with PSS and disease outcome, it alone does not serve as a reliable biomarker for early diagnosis of PSS. Further studies with longer follow-up periods are needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.